Viamet and Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance a Novel Therapy for Cryptococcal Meningitis
Saved in:
| Title: | Viamet and Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance a Novel Therapy for Cryptococcal Meningitis |
|---|---|
| Authors: | Viamet Pharmaceuticals, Inc. and Mycoses Study Group Education & Research Consortium |
| Source: | Business Wire (English). 08/26/2015. |
| Abstract: | Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium (MSGERC) today announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections. This collaboration will combine the antifungal drug discovery and development expertise of Viamet with the strategic clinical development expertise of the MSGERC. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium (MSGERC) today announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections. This collaboration will combine the antifungal drug discovery and development expertise of Viamet with the strategic clinical development expertise of the MSGERC. [ABSTRACT FROM PUBLISHER] |
|---|
